For HCQ, Dr. Fauci demanded well-designed randomized double-blind placebo-controlled trials32,33 and he warned against the use of IVM for treatment.34 In contrast, Fauci green-lighted remdesivir following studies in which the control group did not receive a real placebo.35 Instead, Fauci’s researchers used no placebo in the more severely ailing patients and gave the remaining patients an “active comparator” containing the same treatment protocol agents as used in the remdesivir arm except for substituting sulfobutyl for remdesivir as the test agent.36 Utilization of so-called “toxic” or
...more